Adeona Pharmaceuticals (AEN) Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President

Adeona Pharmaceuticals (AEN) Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President

ANN ARBOR, MI--(Marketwire - 02/09/10) - Adeona Pharmaceuticals, Inc., announced today that it has appointed James S. Kuo, M.D., M.B.A., as Chairman, Chief Executive Officer and President.

Dr. Kuo has been a director of Adeona since February of 2007. In his new role, he will lead the company's growth through independent product launches of its commercialization-stage products and corporate partnering or licensing of its late-stage pharmaceuticals. Previously, Dr. Kuo served as Chairman and CEO of Cordex Pharma, a company developing a portfolio of cardiovascular drugs. He has marketed life science products while at BioMicro Systems and Monarch Labs. In addition, Dr. Kuo has been a licensing executive at Pfizer and Myriad Genetics. He has also been Managing Director of Venture Analysis of HealthCare Ventures. Dr. Kuo received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the Wharton School of Business.

In conjunction with the appointment of Dr. Kuo, Mr. Max Lyon has resigned as President and CEO. Pursuant to the terms of his employment agreement, he has also resigned as a member of the board of directors. Mr. Steve H. Kanzer, whose employment agreement for the past year as full-time executive Chairman for $1 in annual compensation expired on January 9, 2010, will continue to serve as a member of the board of directors.

"The board of directors welcomes Jim's appointment as Chairman, CEO and President," stated Steve H. Kanzer. "He understands the board's strategic directive for the company to become more commercially focused. Jim has a unique combination of skill sets to lead our company. He has been CEO of several publicly-traded companies, launched products in the life science sector, negotiated licensing deals while at large pharma and several biotech companies, and evaluated life science products and completed financings as a venture capitalist."

"It is a pleasure to continue working with the Adeona board in my new capacity as Chairman and CEO," stated James S. Kuo. "Adeona has a tremendous wealth of life science products that we will seek to independently commercialize, establish corporate partnerships or license out."

About Adeona Pharmaceuticals, Inc.

Adeona (AMEX:AEN - News) is a pharmaceutical company focused on the diagnosis and treatment of central nervous systems diseases. In particular, the company has expertise on adult diseases characterized by zinc deficiency and chronic copper toxicity. A 16-center, double-blind, placebo-controlled, Phase 2/3 clinical trial of Adeona's Trimesta? (estriol oral) is currently underway for the treatment of relapsing-remitting multiple sclerosis. In December of 2009, Adeona completed the first controlled clinical trial of oral zinc therapy for the dietary management of Alzheimer's disease and mild cognitive impairment. The company is planning to launch Zinthionein? ZC GS0-150 as a prescription-only medical food. HartLab, an Adeona subsidiary, is a CLIA-certified clinical reference laboratory that exclusively offers the CopperProof Test Panel?, a diagnostic test that measures serum levels of free copper and zinc. For further information, please visit the company's website at www.adeonapharma.com.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.